Image Place holder

Kenneth Wright, PhD

ACD Research Education and Training

Program: Immunology



    • Immunology
    • Malignant Hematology
    • Immuno-Oncology
    • Immuno-Oncology

Education & Training


  • University of Massachusetts, PhD - Cell Biology


  • UNC Lineberger Comp. Cancer Ctr., Postdoctoral Fellow - Immunology

My primary interest is the molecular mechanisms controlling genes involved in antigen presentation. Antigen presentation is a key step in eliciting a normal immune response and it can play an important role in tumor rejection and autoimmunity. The laboratory is currently focused on two transcription factors, CIITA and PRDI-BF1. CIITA is a transcriptional activator and master regulator of the MHC Class II family of antigen presentation genes. PRDI-BF1 is a transcriptional repressor that silences CIITA and promotes terminal differentiation of immune cells. We are examining these factors in the two primary cell types. The first is in B-lymphocytes and during their terminal differentiation into antibody secreting plasma cells. The second is in primary human and mouse dendritic cells. In B-lymphocytes our laboratory has previously mapped the B-cell specific promoter of CIITA. This was done through a combination of in vivo and in vitro DNA binding studies. One of the more significant outcomes of this study was the discovery that the transcriptional silencer PRDI-BF1 down-regulates CIITA and MHC class II expression in multiple myeloma cells. Multiple myeloma is a disease of malignant plasma cells. PRDI-BF1 also down-regulates c-myc, Pax5 and interferon-beta expression. The chromosomal location of PRDI-BF1, 6q21, is deleted in a high percentage of B cell lymphomas as well as other types of cancer. Our investigations have identified a natural truncated form of PRDI-BF1 that is lacking a critical N-terminal domain in multiple myeloma cells and have shown that this isoform is impaired in repressing CIITA transcription. Deletion of this domain from the other two PRDI-BF1 family members converts these proteins from growth suppressive to oncogenic. The role of PRDI-BF1 and its truncated form in the development and progression of multiple myeloma is currently under investigation. We are also characterizing the dendritic cell specific promoter of CIITA in both human and mouse primary dendritic cells. CIITA transcription is high in immature DC cells but is rapidly turned off when the cells receive a maturation signal. We have identified several key transcription factors required for DC expression. The role of these factors as well as the silencing of expression observed upon dendritic cell maturation is an area of continued investigation using multiple approaches including gene knock-out mouse models. These studies will provide vital information for targeting expression of tumor specific antigens directly to the professional antigen presenting dendritic cell with out altering expression in other cells. The mechanism of action of PRDI-BF1 is also being studied. PRDI-BF1 is known to recruit histone deacetylases as part of its transcription repression activity. We have now identified that specific histone methyltransferases are also recruited by PRDI-BF1 and play an important role in its repression activity. This indicates that PRDI-BF1 may serve as a scaffold molecule to bring multiple chromatin modifying enzymes to specific promoters such as CIITA. Investigations are continuing to dissect the role of the histone methyltransferases and PRDI-BF1 in myeloma, lymphoma and dendritic cell development. In addition, a small molecule inhibitor screen is ongoing to identify compounds that interrupt histone methyltransferase activity as potential therapeutics in the treatment of myeloma and lymphoma.


  • Ward GA, Dalton RP, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes. Int J Mol Sci. 2023 Feb.24(4). Pubmedid: 36835307. Pmcid: PMC9966808.
  • Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
  • Ketcher DE, Bidelman A, Le LQ, Otto AK, Lester DK, Amtmann-Beuttner KK, Gonzalez B, Wright KL, Vadaparampil ST, Reblin M, Lau EK. Partnering patients, caregivers, and basic scientists: an engagement model that fosters patient- and family-centered research culture. Transl Res. 2021 Jan.227:64-74. Pubmedid: 32739418. Pmcid: PMC7719089.
  • Watters JM, Wright G, Smith MA, Shah B, Wright KL. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochem Bioph Res Co. 2021 Jan.534:773-779. Pubmedid: 33190829. Pmcid: PMC7785659.
  • Dalton R, Calescibetta A, Zhou JM, Maurin M, Ward G, Trinh TL, Tu N, Gilvary D, Chen X, Cheng P, Kostenko E, Wei S, Wright KL, Eksioglu EA. Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC. Int J Mol Sci. 2021 Jan.22(3). Pubmedid: 33513928. Pmcid: PMC7865632.
  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Front Immunol. 2020 Nov.11:604142. Pubmedid: 33329600. Pmcid: PMC7734315.
  • Yue L, Sharma V, Horvat NP, Akuffo AA, Beatty MS, Murdun C, Colin C, Billington J, Goodheart WE, Sahakian E, Zhang L, Powers JJ, Amin NE, Lambert-Showers QT, Darville LN, Pinilla-Ibarz J, Reuther G, Wright K, Conti C, Lee JY, Zheng X, Ng PY, Martin MW, Marshall CG, Koomen JM, Levine RL, Verma A, Grimes HL, Sotomayor EM, Shao Z, Epling-Burnette PK. HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood. 2020 Jan.135(3):191-207. Pubmedid: 31750881. Pmcid: PMC6966930.
  • Alexander LMM, Watters J, Reusch JA, Maurin M, Nepon-Sixt BS, Vrzalikova K, Alexandrow MG, Murray PG, Wright KL. Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival. Mol Immunol. 2017 Nov.91:8-16. Pubmedid: 28858629. Pmcid: PMC5653440.
  • Alexander LMM, Watters J, Reusch JA, Maurin M, Nepon-Sixt BS, Vrzalikova K, Alexandrow MG, Murray PG, Wright KL. Data supporting the functional role of Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) in B cell lymphoma cell line cells. Data Brief. 2017 Dec.15:222-227. Pubmedid: 29022001. Pmcid: PMC5633249.
  • Reusch JA, Nawandar DM, Wright KL, Kenney SC, Mertz JE. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. J Virol. 2015 Feb.89(3):1731-1743. Pubmedid: 25410866. Pmcid: PMC4300755.
  • Appleyard CB, Antonia SJ, Sullivan DM, Santiago-Cardona PG, Cáceres W, Velez H, Torres-Ruiz JA, Wright KL. Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico. Rev Recent Clin Trials. 2014 Dec.9(4):254-262. Pubmedid: 25626061. Pmcid: PMC4378863.
  • Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013 Oct.3:3042. Pubmedid: 24154688. Pmcid: PMC3807107.
  • Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE, Chen-Kiang S, Moscinski LC, Seto E, Dalton WS, Wright KL, Sotomayor E, Bhalla K, Tao J. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell. 2012 Oct.22(4):506-523. Pubmedid: 23079660. Pmcid: PMC3973134.
  • Vrzalikova K, Leonard S, Fan Y, Bell A, Vockerodt M, Flodr P, Wright KL, Rowe M, Tao Q, Murray PG. Hypomethylation and Over-Expression of the Beta Isoform of BLIMP1 is Induced by Epstein-Barr Virus Infection of B Cells; Potential Implications for the Pathogenesis of EBV-Associated Lymphomas. Pathogens. 2012 Oct.1(2):83-101. Pubmedid: 25436766. Pmcid: PMC4235687.
  • Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC, Dalton WS, Seto E, Wright K, Sotomayor E, Tao J. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012 Jun.31(24):3002-3008. Pubmedid: 22002311. Pmcid: PMC3982396.
  • Cubedo E, Maurin M, Jiang X, Lossos IS, Wright KL. PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL. FEBS J. 2011 Sep.278(17):3065-3075. Pubmedid: 21722313. Pmcid: PMC3158840.
  • Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL, Sotomayor EM, Pinilla-Ibarz JA. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res. 2011 Mar.35(3):394-404. Pubmedid: 20863567. Pmcid: PMC4458853.
  • Smith MA, Wright G, Wu J, Tailor P, Ozato K, Chen X, Wei S, Piskurich JF, Ting JP, Wright KL. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem. 2011 Mar.286(10):7893-7904. Pubmedid: 21216962. Pmcid: PMC3048676.
  • Vrzalikova K, Vockerodt M, Leonard S, Bell A, Wei W, Schrader A, Wright KL, Kube D, Rowe M, Woodman CB, Murray PG. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood. 2011 Jun.117(22):5907-5917. Pubmedid: 21411757. Pmcid: PMC3293751.
  • Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC, Dalton WS, Sotomayor EM, Wright KL, Tao J. Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia. 2011 Jan.25(1):145-152. Pubmedid: 20966935. Pmcid: PMC3083119.
  • Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, Vicente-Suarez I, Pinilla-Ibarz J, Wright KL, Seto E, Bhalla K, Villagra A, Sotomayor EM. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol. 2011 Apr.186(7):3986-3996. Pubmedid: 21368229. Pmcid: PMC3998678.
  • Smith MA, Maurin M, Cho HI, Becknell B, Freud AG, Yu J, Wei S, Djeu J, Celis E, Caligiuri MA, Wright KL. PRDM1/Blimp-1 controls effector cytokine production in human NK cells. J Immunol. 2010 Nov.185(10):6058-6067. Pubmedid: 20944005. Pmcid: PMC3864810.
  • Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, Sotomayor E, Wright KL. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010 Jun.8(6):907-918. Pubmedid: 20530581. Pmcid: PMC2891394.
  • Lwin T, Lin J, Choi YS, Zhang X, Moscinski LC, Wright KL, Sotomayor EM, Dalton WS, Tao J. Follicular dendritic cell-dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion-mediated Bim down-regulation through induction of microRNA-181a. Blood. 2010 Dec.116(24):5228-5236. Pubmedid: 20841506. Pmcid: PMC3012540.
  • Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan ZM, Jenuwein T, Marine JC, Wright KL, Chen J. MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. Embo J. 2010 Aug.29(15):2538-2552. Pubmedid: 20588255. Pmcid: PMC2928696.
  • Desai S, Bolick SC, Maurin M, Wright KL. PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells. J Immunol. 2009 Nov.183(9):5778-5787. Pubmedid: 19828640. Pmcid: PMC3164282.
  • Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M, Nguyen D, Wright KL, Atadja PW, Bhalla K, Pinilla-Ibarz J, Seto E, Sotomayor EM. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan.10(1):92-100. Pubmedid: 19011628. Pmcid: PMC3925685.
  • Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008 Jan.153(2):263-270. Pubmedid: 17906675. Pmcid: PMC2219529.
  • Bewry NN, Bolick SC, Wright KL, Harton JA. GTP-dependent recruitment of CIITA to the class II major histocompatibility complex promoter. J Biol Chem. 2007 Sep.282(36):26178-26184. Pubmedid: 17623662.
  • Coopman K, Smith LD, Wright KL, Ward SG. Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol. 2007 Mar.7(3):360-371. Pubmedid: 17276894.
  • Chen H, Gilbert CA, Hudson JA, Bolick SC, Wright KL, Piskurich JF. Positive regulatory domain I-binding factor 1 mediates repression of the MHC class II transactivator (CIITA) type IV promoter. Mol Immunol. 2007 Feb.44(6):1461-1470. Pubmedid: 16765445. Pmcid: PMC1987354.
  • Zhao M, Flynt FL, Hong M, Chen H, Gilbert CA, Briley NT, Bolick SC, Wright KL, Piskurich JF. MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma. Mol Immunol. 2007 Apr.44(11):2923-2932. Pubmedid: 17300840. Pmcid: PMC1892219.
  • Wright K, Ting J. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 2006 Sep.27(9):405-412. Pubmedid: 16870508.
  • Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, Chellappan S. Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol. 2006 Jun.26(11):4161-4171. Pubmedid: 16705168. Pmcid: PMC1489107.
  • Piskurich JG, Gilbert CA, Ashley BD, Zhao M, Chen H, Wu J, Bolick SC, Wright KL. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Mol Immunol. 2006 Feb.43(6):519-528. Pubmedid: 15950283. Pmcid: PMC1482792.
  • Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, Briggs J, Karras J, Cress WD, Pardoll D, Jove R, Chen J, Yu H. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005 Sep.25(17):7432-7440. Pubmedid: 16107692. Pmcid: PMC1190305.
  • Wang AH, Gregoire S, Zika E, Xiao L, Li CS, Li H, Wright KL, Ting J, Yang XJ. Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases. J Biol Chem. 2005 Aug.280(32):29117-29127. Pubmedid: 15964851.
  • Gyory I, Wu J, Fejer G, Seto E, Wright K. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol. 2004 Mar.5(3):299-308. Pubmedid: 14985713.
  • Gyory I, Fejer G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol. 2003 Mar.170(6):3125-3133. Pubmedid: 12626569.
  • Rezai-Zadeh N, Zhang X, Namour F, Fejer G, Wen YD, Yao YL, Gyory I, Wright K, Seto E. Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Gene Dev. 2003 Apr.17(8):1019-1029. Pubmedid: 12704081. Pmcid: PMC196041.
  • Wong AW, Ghosh N, McKinnon KP, Reed W, Piskurich JF, Wright KL, Ting JP. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol. 2002 Sep.169(6):3112-3119. Pubmedid: 12218128.
  • Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002 Mar.21(13):2000-2008. Pubmedid: 11960372.
  • Jennings R, Alsarraj M, Wright K, Munoz-Antonia T. Regulation of the human transforming growth factor beta type II receptor gene promoter by novel Sp1 sites. Oncogene. 2001 Oct.20(47):6899-6909. Pubmedid: 11687969.
  • Ghosh N, Gyory I, Wright G, Wood J, Wright K. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J Biol Chem. 2001 May.276(18):15264-15268. Pubmedid: 11279146.
  • Goodwin B, Xi H, Tejiram R, Eason D, Ghosh D, Wright K, Nagarajan U, Boss J, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001 Jun.12(6):327-335. Pubmedid: 11432807.
  • Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res. 2000 Oct.60(20):5789-5796. Pubmedid: 11059775.
  • Chatterjee-Kishore M, Wright K, Ting J, Stark G. How Stat1 mediates constitutive gene expression: a complex of unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. Embo J. 2000 Aug.19(15):4111-4122. Pubmedid: 10921891. Pmcid: PMC306607.
  • Xi H, Eason D, Ghosh D, Dovhey S, Wright K, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999 Oct.18(43):5889-5903. Pubmedid: 10557076.
  • Ghosh N, Piskurich J, Wright G, Hassani K, Ting J, Wright K. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transactivator in B-lymphocytes. J Biol Chem. 1999 Nov.274(45):32342-32350. Pubmedid: 10542275.
  • Jackson R, Antonia S, Wright K, Moon S, Nepvue A, Munoz-Antonia T. Human cut-like repressor protein binds TGFbeta type II receptor gene promoter. Arch Biochem Biophys. 1999 Nov.371(2):290-300. Pubmedid: 10545217.
  • Brickey WJ, Wright KL, Zhu XS, Ting JP. Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor. J Immunol. 1999 Dec.163(12):6622-6630. Pubmedid: 10586057.
  • Wright K, Chin K, Linhoff M, Skinner C, Brown J, Boss J, Stark G, Ting J. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo. Proc Natl Acad Sci U S A. 1998 May.95(11):6267-6272. Pubmedid: 9600954. Pmcid: PMC27653.
  • Zimmermann A, Wright K, Ting J, Mitchell B. Regulation of inosine-5'-monophosphate dehydrogenase type II gene expression in human T cells. Role for a novel 5' palindromic octamer sequence. J Biol Chem. 1997 Sep.272(36):22913-22923. Pubmedid: 9278455.
  • Katula KS, Wright KL, Paul H, Surman DR, Nuckolls FJ, Smith JW, Ting JP, Yates J, Cogswell JP. Cyclin-dependent kinase activation and S-phase induction of the cyclin B1 gene are linked through the CCAAT elements. Cell Growth Differ. 1997 Jul.8(7):811-820. Pubmedid: 9218875.
  • Ting J, Wright K, Chin K, Brickey W, Li G. The DMB promoter: delineation, in vivo footprint, trans-activation, and trans-dominant suppression. J Immunol. 1997 Dec.159(11):5457-5462. Pubmedid: 9548486.
  • Linhoff M, Wright K, Ting J. CCAAT-binding factor NF-Y and RFX are required for in vivo assembly of a nucleoprotein complex that spans 250 base pairs: the invariant chain promoter as a model. Mol Cell Biol. 1997 Aug.17(8):4589-4596. Pubmedid: 9234716. Pmcid: PMC232312.
  • White L, Wright K, Felix N, Ruffner H, Reis L, Pine R, Ting J. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice. Immunity. 1996 Oct.5(4):365-376. Pubmedid: 8885869.
  • Wright KL, Moore TL, Vilen BJ, Brown AM, Ting JP. Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem. 1995 Sep.270(36):20978-20986. Pubmedid: 7673122.
  • Birnbaum MJ, Wright KL, van Wijnen AJ, Ramsey-Ewing AL, Bourke MT, Last TJ, Aziz F, Frenkel B, Rao BR, Aronin N. Functional role for Sp1 in the transcriptional amplification of a cell cycle regulated histone H4 gene. Biochemistry-Us. 1995 Jun.34(23):7648-7658. Pubmedid: 7779811.
  • Wright KL, White LC, Kelly A, Beck S, Trowsdale J, Ting JP. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med. 1995 Apr.181(4):1459-1471. Pubmedid: 7699330. Pmcid: PMC2191963.
  • Wright KL, Vilen BJ, Itoh-Lindstrom Y, Moore TL, Li G, Criscitiello M, Cogswell P, Clarke JB, Ting JP. CCAAT box binding protein NF-Y facilitates in vivo recruitment of upstream DNA binding transcription factors. Embo J. 1994 Sep.13(17):4042-4053. Pubmedid: 8076600. Pmcid: PMC395325.
  • Chin KC, Mao C, Skinner C, Riley JL, Wright KL, Moreno CS, Stark GR, Boss JM, Ting JP. Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. Immunity. 1994 Nov.1(8):687-697. Pubmedid: 7600294.
  • Dworetzky SI, Wright KL, Fey EG, Penman S, Lian JB, Stein JL, Stein GS. Sequence-specific DNA-binding proteins are components of a nuclear matrix-attachment site. Proc Natl Acad Sci U S A. 1992 May.89(9):4178-4182. Pubmedid: 1570345. Pmcid: PMC525656.
  • Wright KL, Dell'Orco RT, van Wijnen AJ, Stein JL, Stein GS. Multiple mechanisms regulate the proliferation-specific histone gene transcription factor HiNF-D in normal human diploid fibroblasts. Biochemistry-Us. 1992 Mar.31(10):2812-2818. Pubmedid: 1547221.
  • Wright KL, Ting JP. In vivo footprint analysis of the HLA-DRA gene promoter: cell-specific interaction at the octamer site and up-regulation of X box binding by interferon gamma. Proc Natl Acad Sci U S A. 1992 Aug.89(16):7601-7605. Pubmedid: 1502171. Pmcid: PMC49758.
  • van Wijnen AJ, Choi TK, Owen TA, Wright KL, Lian JB, Jaenisch R, Stein JL, Stein GS. Involvement of the cell cycle-regulated nuclear factor HiNF-D in cell growth control of a human H4 histone gene during hepatic development in transgenic mice. Proc Natl Acad Sci U S A. 1991 Mar.88(6):2573-2577. Pubmedid: 2006193. Pmcid: PMC51275.
  • Holthuis J, Owen TA, van Wijnen AJ, Wright KL, Ramsey-Ewing A, Kennedy MB, Carter R, Cosenza SC, Soprano KJ, Lian JB. Tumor cells exhibit deregulation of the cell cycle histone gene promoter factor HiNF-D. Science. 1990 Mar.247(4949 Pt 1):1454-1457. Pubmedid: 2321007.
  • Owen TA, Bortell R, Yocum SA, Smock SL, Zhang M, Abate C, Shalhoub V, Aronin N, Wright KL, van Wijnen AJ. Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene: model for phenotype suppression of transcription. Proc Natl Acad Sci U S A. 1990 Dec.87(24):9990-9994. Pubmedid: 2124710. Pmcid: PMC55300.
  • Stein GS, Stein JL, Lian JB, Van Wijnen AJ, Wright KL, Pauli U. Modifications in molecular mechanisms associated with control of cell cycle regulated human histone gene expression during differentiation. Cell Biophys. 1989 Dec.15(3):201-223. Pubmedid: 2480181.
  • McConnell HM, Wright KL, McFarland BG. The fraction of the lipid in a biological membrane that is in a fluid state: a spin label assay. Biochem Bioph Res Co. 1972 Apr.47(1):273-281. Pubmedid: 4337427.
  • Wright KL, Morgan D, Yu X, Goss J, Salbaum K, Duff K, Gordon M. Mice transgenic for a human amyloid precursor protein promoter-lacZ reporter construct. J Mol Neurosci. 13(1-2):111-120. Pubmedid: 10691298.


  • Title: Determine the effects of the TP-0184 and its derivatives (second generation) on myeloid-derived suppressor cell (MDSC)-mediated suppressive functions and improve the local bone marrow (BM) microenvironment in patients with MDS
    Sponsor: Sumitomo Pharma Oncology
    PI (Contact): Wright, K., PI: Eksioglu, E.
  • Title: Institutional Research Grant - Moffitt Cancer Center
    Sponsor: Amer Cancer Society
    PI: Wright, K.
  • Title: Moffitt Cancer Center Support Grant Years 24-27
    Sponsor: Nat Institutes of Health
    PI: Cleveland, J., Project PI: Kanetsky, P., Project PI: Kissil, J., Project PI: Brandon, T., Project PI: Conejo-Garcia, J., Project PI: Duckett, D., Project PI: Gray, J., Project PI: Jim, H., Project PI: Locke, F., Core PI/Director: Springer, B., Core PI/Director: Vadaparampil, S., Core PI/Director: Wright, K., Core PI/Director: Rodriguez, P.
  • Title: 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
    Sponsor: Nat Institutes of Health
    PI (Contact): Wright, K., PI (MPI): Monteiro, A.